| An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) (NCT07217860) | Xenon Pharmaceuticals Inc. | 2025-10-30 |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) (NCT07172516) | Xenon Pharmaceuticals Inc. | 2025-08-08 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) (NCT07076407) | Xenon Pharmaceuticals Inc. | 2025-07-08 |
| An Open-Label Study of Azetukalner in Major Depressive Disorder (NCT06922110) | Xenon Pharmaceuticals Inc. | 2025-03-18 |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (NCT06775379) | Xenon Pharmaceuticals Inc. | 2024-12-20 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) (NCT05716100) | Xenon Pharmaceuticals Inc. | 2023-05-09 |
| An Open-label Study of XEN1101 in Epilepsy (NCT05718817) | Xenon Pharmaceuticals Inc. | 2023-04-25 |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (NCT05667142) | Xenon Pharmaceuticals Inc. | 2023-02-14 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder (NCT05376150) | Xenon Pharmaceuticals Inc. | 2022-05-19 |
| An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE (NCT04912856) | Xenon Pharmaceuticals Inc. | 2021-08-17 |
| Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101 (NCT04952467) | Xenon Pharmaceuticals Inc. | 2021-07-14 |
| XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (NCT04639310) | Xenon Pharmaceuticals Inc. | 2021-03-29 |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy (NCT03796962) | Xenon Pharmaceuticals Inc. | 2019-01-30 |
| Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 (NCT03467100) | Xenon Pharmaceuticals Inc. | 2018-02-19 |
| Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101 (NCT03468725) | Xenon Pharmaceuticals Inc. | 2018-02-13 |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101. (NCT03340220) | Xenon Pharmaceuticals Inc. | 2017-11-13 |